The Immunomodulatory Properties of Mesenchymal Stem Cells: Implications for Surgical Disease

被引：23

作者：

Weil, Brent R. ^{[1
]}

Manukyan, Mariuxi C. ^{[1
]}

Herrmann, Jeremy L. ^{[1
]}

Abarbanell, Aaron M. ^{[1
]}

Poynter, Jeffrey A. ^{[1
]}

Wang, Yue ^{[1
]}

Meldrum, Daniel R. ^{[1
,2
,3
,4
]}

机构：

[1] Indiana Univ, Sch Med, Dept Surg, Indianapolis, IN 46202 USA

[2] Indiana Univ, Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA

[3] Indiana Univ, Sch Med, Ctr Immunobiol, Indianapolis, IN 46202 USA

[4] Methodist Hosp, Clarian Cardiovasc Surg, Indianapolis, IN USA

来源：

JOURNAL OF SURGICAL RESEARCH | 2011年 / 167卷 / 01期

关键词：

Crohn's disease; transplant; sepsis; SIRS; cancer; tumor; inflammation; immunomodulation; immunoprivilege; MARROW STROMAL CELLS; BONE-MARROW; LYMPHOCYTE-PROLIFERATION; MIXED CHIMERISM; TUMOR-GROWTH; IN-VITRO; INHIBIT; TRANSPLANTATION; ENHANCE; MSCS;

D O I：

10.1016/j.jss.2010.07.019

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

Mesenchymal stem cells (MSCs) have been used experimentally and clinically in the treatment of a wide variety of pathologies. It is now clear that a number of different mechanisms contribute to the therapeutic effects exerted by these cells. The ability of MSCs to interact with and modulate the functions of a wide variety of immune cells has been recognized as one such mechanism. The implications that the immunomodulatory properties of MSCs may have for the treatment of solid organ rejection, the Systemic Inflammatory Response Syndrome, cancer, and Crohn's disease are reviewed herein. (C) 2011 Elsevier Inc. All rights reserved.

引用

页码：78 / 86

页数：9

共 72 条

[1] Human mesenchymal stem cells modulate allogeneic immune cell responses [J].

Aggarwal, S ;

Pittenger, MF .

BLOOD, 2005, 105 (04) :1815-1822

[2] Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care [J].

Angus, DC ;

Linde-Zwirble, WT ;

Lidicker, J ;

Clermont, G ;

Carcillo, J ;

Pinsky, MR .

CRITICAL CARE MEDICINE, 2001, 29 (07) :1303-1310

[3] Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway [J].

Augello, A ;

Tasso, R ;

Negrini, SM ;

Amateis, A ;

Indiveri, F ;

Cancedda, R ;

Pennesi, G .

EUROPEAN JOURNAL OF IMMUNOLOGY, 2005, 35 (05) :1482-1490

[4] Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo [J].

Bartholomew, A ;

Sturgeon, C ;

Siatskas, M ;

Ferrer, K ;

McIntosh, K ;

Patil, S ;

Hardy, W ;

Devine, S ;

Ucker, D ;

Deans, R ;

Moseley, A ;

Hoffman, R .

EXPERIMENTAL HEMATOLOGY, 2002, 30 (01) :42-48

[5] Mesenchymal Stem Cells in the Induction of Transplantation Tolerance [J].

Bartholomew, Amelia ;

Polchert, David ;

Szilagyi, Erzsebet ;

Douglas, G. W. ;

Kenyon, Norma .

TRANSPLANTATION, 2009, 87 (09) :S55-S57

[6] MESENCHYMAL STEM-CELLS [J].

CAPLAN, AI .

JOURNAL OF ORTHOPAEDIC RESEARCH, 1991, 9 (05) :641-650

[7] Why are MSCs therapeutic? New data: new insight [J].

Caplan, Al .

JOURNAL OF PATHOLOGY, 2009, 217 (02) :318-324

[8] Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease [J].

Cassinotti, A. ;

Annaloro, C. ;

Ardizzone, S. ;

Onida, F. ;

Della Volpe, A. ;

Clerici, M. ;

Usardi, P. ;

Greco, S. ;

Maconi, G. ;

Porro, G. Bianchi ;

Deliliers, G. Lambertenghi .

GUT, 2008, 57 (02) :211-217

[9] Human fetal mesenchymal stem cells as vehicles for gene delivery [J].

Chan, J ;

O'Donoghue, K ;

De la Fuente, J ;

Roberts, IA ;

Kumar, S ;

Morgan, JE ;

Fisk, NM .

STEM CELLS, 2005, 23 (01) :93-102

[10]

Chang SCN, 2004, J SURG RES, V119, P85, DOI 10.1016/j.jss.2003.08.003

← 1 2 3 4 5 6 7 8 →